Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference
Enochian BioSciences (NASDAQ: ENOB) is set to present its cutting-edge therapies for HIV, Hepatitis B, and Oncology at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enochian BioSciences (NASDAQ: ENOB) is set to present its cutting-edge therapies for HIV, Hepatitis B, and Oncology at the H.C. Wainwright 22nd Annual Global Investment Conference. The presentation will occur on September 15, 2020, at 2:00 PM Eastern, led by Executive Vice Chair Dr. Mark Dybul. Investors are invited to join a live virtual session and can also participate in one-on-one meetings. Further details and a link to the webcast can be found on Enochian's website.
Details
News Market Reaction – ENOB
The recorded move for ENOB in the trading session of this news was +1.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference.
Enochian BioSciences’ Executive Vice Chair, Dr. Mark Dybul, will be presenting to a live virtual audience on Tuesday, September 15, 2020 at 2:00 pm Eastern, and will be participating in one-on-one meetings with investors who are registered to attend the conference. A link to the live and archived webcast may be accessed on Enochian’s website under the Investors/Media section in Events and Presentations.
More information on the conference may be found at H.C. Wainwright’s conference website.
About Enochian BioSciences Inc.
Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV and Oncology.
Forward-Looking Statements
Statements in this presentation that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.